SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-059522
Filing Date
2024-05-14
Accepted
2024-05-14 16:06:16
Documents
13
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K pstx-20240514.htm   iXBRL 8-K 40867
2 EX-99.1 pstx-ex99_1.htm EX-99.1 97425
3 GRAPHIC img265366334_0.jpg GRAPHIC 25951
  Complete submission text file 0000950170-24-059522.txt   300393

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240514.xsd EX-101.SCH 24823
16 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240514_htm.xml XML 4723
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 24944265
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)